Suppr超能文献

在接受标准全身照射、环磷酰胺和氟达拉滨减低剂量预处理的双份脐血异基因干细胞移植的成年患者中,早期单核细胞和总淋巴细胞计数较高与更好的总生存率相关。

Higher Early Monocyte and Total Lymphocyte Counts Are Associated with Better Overall Survival after Standard Total Body Irradiation, Cyclophosphamide, and Fludarabine Reduced-Intensity Conditioning Double Umbilical Cord Blood Allogeneic Stem Cell Transplantation in Adults.

作者信息

Le Bourgeois Amandine, Peterlin Pierre, Guillaume Thierry, Delaunay Jacques, Duquesne Alix, Le Gouill Steven, Moreau Philippe, Mohty Mohamad, Campion Loïc, Chevallier Patrice

机构信息

Centre Hospitalier et Universitaire de Nantes, Département d'Hématologie Clinique, Centre d'Investigation Clinique en Cancérologie (CI2C), Nantes, France.

Centre Hospitalier et Universitaire de Nantes, Département d'Hématologie Clinique, Centre d'Investigation Clinique en Cancérologie (CI2C), Nantes, France.

出版信息

Biol Blood Marrow Transplant. 2016 Aug;22(8):1473-1479. doi: 10.1016/j.bbmt.2016.04.015. Epub 2016 Apr 24.

Abstract

This single-center retrospective study aimed to report the impact of early hematopoietic and immune recoveries after a standard total body irradiation, cyclophosphamide, and fludarabine (TCF) reduced-intensity conditioning (RIC) regimen for double umbilical cord blood (dUCB) allogeneic stem cell transplantation (allo-SCT) in adults. We analyzed 47 consecutive patients older than 17 years who engrafted after a dUCB TCF allo-SCT performed between January 2006 and April 2013 in our department. Median times for neutrophil and platelet recoveries were 17 (range, 6 to 59) and 37 days (range, 0 to 164), respectively. The 3-year overall (OS) and disease-free survivals, relapse incidence, and nonrelapse mortality were 65.7%, 57.2%, 27.1%, and 19%, respectively. In multivariate analysis, higher day +30 monocyte (≥615/mm(3); hazard ratio [HR], .04; 95% confidence interval [CI], .004 to .36; P < .01) and day +42 lymphocyte (≥395/mm(3); HR, .16; 95% CI, .03 to .78; P = .02) counts were independently associated with better OS. These results suggest that early higher hematopoietic and immune recovery is predictive of survival after dUCB TCF RIC allo-SCT in adults. Factors other than granulocyte colony-stimulating factor, which was used in all cases, favoring expansion of monocytes or lymphocytes, should be tested in the future as part of the UCB transplantation procedure.

摘要

本单中心回顾性研究旨在报告在标准全身照射、环磷酰胺和氟达拉滨(TCF)减低强度预处理(RIC)方案用于成人双份脐带血(dUCB)异基因干细胞移植(allo-SCT)后早期造血和免疫恢复的影响。我们分析了2006年1月至2013年4月在我科接受dUCB TCF allo-SCT后植入的47例年龄超过17岁的连续患者。中性粒细胞和血小板恢复的中位时间分别为17天(范围6至59天)和37天(范围0至164天)。3年总生存率(OS)、无病生存率、复发率和非复发死亡率分别为65.7%、57.2%、27.1%和19%。多因素分析显示,较高的+30天单核细胞计数(≥615/mm³;风险比[HR],0.04;95%置信区间[CI],0.004至0.36;P<0.01)和+42天淋巴细胞计数(≥395/mm³;HR,0.16;95%CI,0.03至0.78;P=0.02)与更好的OS独立相关。这些结果表明,早期较高的造血和免疫恢复可预测成人dUCB TCF RIC allo-SCT后的生存情况。除了所有病例均使用的粒细胞集落刺激因子外,有利于单核细胞或淋巴细胞扩增的其他因素,未来应作为脐带血移植程序的一部分进行测试。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验